SCHEMBL6696936

SCHEMBL6696936

[CH2]Cc1cscc1NS(=O)(=O)c1cccc(Cl)c1C

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 1/20 0.52
HSD11B1 P28845 10/20 0.51
EDNRB P24530 2/20 0.49
EDNRA P25101 2/20 0.49
HSD17B1 P14061 2/20 0.45
HSD17B2 P37059 2/20 0.45
CCR4 P51679 1/20 0.44
PKM P14618 1/20 0.40
F2 P00734 1/20 0.40
POLB P06746 1/20 0.40
CASP6 P55212 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PTGES2 Q9H7Z7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6614224 0.85 SLC40A1 (0.50) SLC40A1HSD11B1EDNRBEDNRAHSD17B1
SCHEMBL6611146 0.85 SLC40A1 (0.50) SLC40A1HSD11B1EDNRBEDNRAHSD17B1
SCHEMBL6609592 0.84 HSD11B1 (0.50) SLC40A1HSD11B1EDNRBEDNRAHSD17B1
SCHEMBL6610981 0.83 SLC40A1 (0.48) SLC40A1HSD11B1EDNRBEDNRAHSD17B1
SCHEMBL6610782 0.83 HSD11B1 (0.49) SLC40A1HSD11B1EDNRBEDNRAHSD17B1
SCHEMBL6611877 0.82 SLC40A1 (0.47) SLC40A1HSD11B1EDNRBEDNRAHSD17B1
SCHEMBL6614236 0.82 HSD11B1 (0.48) SLC40A1HSD11B1EDNRBEDNRAHSD17B1
SCHEMBL6613191 0.82 SLC40A1 (0.47) SLC40A1HSD11B1EDNRBEDNRAHSD17B1
SCHEMBL6612021 0.82 HSD11B1 (0.48) SLC40A1HSD11B1EDNRBEDNRAHSD17B1
SCHEMBL6612335 0.82 SLC40A1 (0.49) SLC40A1HSD11B1EDNRBEDNRAHSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019075394-A1 COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME VANDERKLISH PETER (US) 2019-04-18 WO disclosed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed